Logo

GeneDx to Execute 1-for-33 Reverse Stock Split

Apr 28, 2023 | staff reporter

NEW YORK – GeneDx said Friday that its board of directors has approved a 1-for-33 reverse stock split of its common stock. The move, which will take effect May 4, is intended to help the firm regain compliance with the Nasdaq's minimum bid price listing requirement of $1 per share.

The reverse stock split will reduce the number of outstanding GeneDx shares to about 25.6 million from 844.4 million.

The Stamford, Connecticut-based company, formerly known as Sema4, received a notice of noncompliance from the Nasdaq on Dec. 28 because its stock price had been below $1 per share for 30 consecutive trading days. GeneDx posted a net loss of $549.0 million in 2022.

GeneDx shares were down 6 percent at $.25 in the first half hour of trading Friday.

Filed under

Business News
Molecular Diagnostics
North America
GeneDx
Sema4
stock split
Nasdaq
Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.